Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 May 25;57(6):930–938. doi: 10.1002/pbc.23174

Table II.

Clinical characteristics of patients with high, intermediate, and low GLI1 expression

GLI1/18S ratio High
(n=15)		 Intermediatez
(n=27)		 Low
(n=28)
Age (years) (p=0.64) <5
5 to <10
10 to <15
> or =15		 5 (16%)
6 (23%)
3 (50%)
1 (25%)		 15 (47%)
10 (38%)
1 (17%)
1 (25%)		 12 (38%)
10 (38%)
2 (33%)
2 (50%)
Gender (p=0.48) Male
Female		 9 (20%)
6 (27%)		 17 (37%)
10 (45%)		 20 (43%)
6 (27%)
Race (p=0.73) White
Non-white		 11 (26%)
4 (16%)		 16 (37%)
11 (44%)		 16 (37%)
10 (40%)
IRSG tumor stage
(p=0.83)		 1
2
3
4		 4 (22%)
2 (18%)
8 (25%)
1 (14%)		 6 (33%)
3 (27%)
14 (44%)
4 (57%)		 8 (44%)
6 (55%)
10 (31%)
2 (29%)
Clinical group (p=0.39) I
II
III
IV		 3 (19%)
1 (13%)
10 (27%)
1 (14%)		 6 (38%)
1 (13%)
16 (43%)
4 (57%)		 7 (44%)
6 (75%)
11 (30%)
2 (29%)
Primary tumor site
(p=1.0 favorable vs.
*unfavorable)		 Orbit
Head/Neck
*Parameningeal
GU (non-bladder
or prostate)
*Bladder/Prostate
*Extremity
Other		 1
3
3
1

2
1
4		 -
4
10
4

5
1
3		 2
-
9
6

4
1
4
Tumor size (p=0.86) <5cm
>5cm
Unknown		 5 (17%)
8 (23%)
2		 13 (43%)
13 (37%)
1		 12 (40%)
14 (40%)
-